What is the Market's View on Mersana Therapeutics Inc (MRSN) Stock's Price and Volume Trends Thursday?

Overall market sentiment has been down on Mersana Therapeutics Inc (MRSN) stock lately. MRSN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Mersana Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MRSN!

See Full MRSN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With MRSN Stock Today?

Mersana Therapeutics Inc (MRSN) stock has gained 8.56% while the S&P 500 has fallen -1.11% as of 12:20 PM on Thursday, Oct 26. MRSN is higher by $0.10 from the previous closing price of $1.11 on volume of 641,908 shares. Over the past year the S&P 500 is higher by 7.29% while MRSN has fallen -83.12%. MRSN lost -$2.05 per share in the over the last 12 months. To screen for more stocks like Mersana Therapeutics Inc click here.

More About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.